Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5?-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Abstract: Cargo assemblages including a pallet, a load of packages arranged in one or more layers, and a support layer, in which the support layer is sized and positioned within the cargo assemblage to support and/or stabilize the cargo, thereby providing improved pallet efficiency, improved shipping efficiency, and/or improved stability.

Abstract: Disclosed is a method of forming a glass article. In the method, a mid-frame is adhered to a glass sheet in a flat configuration. The glass sheet has a first major surface and a second major surface opposite to the first major surface. The mid-frame is adhered to the second major surface of the glass sheet. The glass sheet and mid-frame are bent over a forming surface of a chuck so that the glass sheet is in a curved configuration. The forming surface includes a first radius of curvature of 20 mm or more, and the first major surface of the glass sheet conforms to the forming surface. A frame is attached to the mid-frame, and the frame holds the glass sheet in the curved configuration.

Abstract: An external catheter system is provided. The external catheter system includes an elongated sheath having an open upper end and an open lower end and a check valve. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring. The check valve has a generally conical shape and is inserted into the elongated sheath and is disposed before the drainage tube and sits within the elongated sheath.

Abstract: An external catheter system is provided. The system includes an elongated sheath having an open upper end and an open lower end. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring.

Abstract: An external catheter system is provided. The system includes an elongated sheath having an open upper end and an open lower end. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring.

Abstract: Data-persisting temporary virtual machine environments are described. A computing system enables a user to access a virtual machine and a virtual data store in a temporary virtual machine environment in response to receiving a user request to access the temporary virtual machine environment. The computing system stores data as virtual data store data in the virtual data store in response to receiving the data from the user. The computing system creates a copy of the virtual data store data if all users are signed off from use of the temporary virtual machine environment. The computing system deletes the virtual machine and the virtual data store. The computing system receives a request by a specific user to access the temporary virtual machine environment, and enables the specific user to access a recreated virtual machine and the copy of the virtual data store data.

Abstract: Data-persisting temporary virtual machine environments are described. A computing system enables a user to access a virtual machine and a virtual data store in a temporary virtual machine environment in response to receiving a user request to access the temporary virtual machine environment. The computing system stores data as virtual data store data in the virtual data store in response to receiving the data from the user. The computing system creates a copy of the virtual data store data if all users are signed off from use of the temporary virtual machine environment. The computing system deletes the virtual machine and the virtual data store. The computing system receives a request by a specific user to access the temporary virtual machine environment, and enables the specific user to access a recreated virtual machine and the copy of the virtual data store data.

Abstract: Techniques for managing a return request may be provided. For example, a user may want to return an item that the user received from an item provider via an electronic marketplace. The user can take a picture of the item and transmit the image to a computer that determines that the user would like to return the item. The computer may also determine that the item is returnable (e.g., was provided to the user within an allowable timeframe, satisfies a constraint for returning the item). The computer can initiate a return of the item. In some examples, the computer can also determine a convenient return location or the reason that the user is returning the item to the item provider.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses 211 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the ALK-NPM translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein Kinases (including Receptor Tyrosine Kinases), Adaptor/Scaffold Proteins, Cellular Metabolism or Miscellaneous Enzymes, Oxidoreductases, Transcription Factors, Cytoskeletal Proteins, Translation Initiation Complexes, RNA Binding Proteins, Proteases, Acetyltransferases, G protein regulators/GTPases, Helicases, Apoptosis/Cell Cycle Regulation proteins, and Hydrolases.

Abstract: The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

Abstract: The invention discloses 102 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of c-Src kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Actin Binding proteins, Cytoskeletal proteins, G protein/GTPase Activating protein/Guanine Nucleotide Exchange Factor proteins, Helicases, RNA Binding proteins, Transcription/Translation Factor or Initiation Complex proteins, Cellular Metabolism Enzymes, and Vesicle proteins.

Abstract: The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeleton proteins, GTP Signaling proteins, Kinases, Metabolism proteins, Phosphatases/Phospho-diesterases/Proteases, Receptor proteins, RNA Processing proteins, Transcription proteins, Translation proteins, Transporter proteins, and Ubitquitin proteins, as well as other protein types.

Abstract: The invention discloses 95 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of the T-cell receptor, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.